Chris Sweda/Chicago Tribune/Getty Images

Horowitz: Paxlovid and the need to end human experimentation

The more you “pax,” the more you vaxx.

You have to hand it to Pfizer. The company concocted a brilliant marketing strategy for two products that self-fulfill a need for each other. The more you vaxx, the more likely you are to get COVID. Then they offer the therapeutic Paxlovid upon getting the virus, in which case you get a rebound of the virus and take even more Paxlovid. Then, because of the rebound, you are so scared that you get more boosters, which of course, erase your natural immunity and make it even more likely that you get the virus again … and need Pfizer’s pair of products a second time. Rinse and repeat while Pfizer’s Albert Bourla and his FDA and NIH cronies laugh all the way to the bank.

What is the statistical likelihood that the president, the first lady, the CDC director, and Dr. Fauci all got the virus shortly after their booster shots and all got a rebound of the virus after taking Paxlovid – if it’s really a rare phenomenon? On Monday, CDC Director Rochelle Walensky announced that three weeks after getting her fifth COVID shot in less than two years and contracting COVID nonetheless, and a week after taking Paxlovid, she got the mysterious “Paxlovid rebound” and tested positive again. How can the government continue to support, market, and endorse both of these products after all of the known and unknown problems – after the president himself conceded the emergency is over?

Consider the following: Paxlovid is an experimental drug mixed with a heavy-duty AIDS drug with over 30 categories of contraindications with common medicines that most seniors take. It clearly causes a rebound of the virus, which is already mild to begin with for the Omicron variants, and leaves people with a metallic taste in their mouths. No long-term genotoxicity and carcinogenicity studies were conducted, and a new study shows that it might cause blood clots, just like the Pfizer shots. Yet this drug is being funded by the government and now being dispensed at pharmacies without a doctor’s prescription, while safe, Nobel Prize-winning drugs are being denied by pharmacists even with a doctor’s prescription!

But they are not done yet. Now, the NIH is rewarding Pfizer’s executives for their malfeasance by studying Paxlovid as the first candidate for “long COVID treatment.” This is the brilliance of their marketing at work. If their products actually worked, they would only make a finite amount of money. But with their products causing counterproductive reactions and relapses of the virus, they create a perpetual circuitous cycle and pretext to use them over and over again at “the speed of science.” Paxlovid has brought in $7.5 billion in sales just for Q3 alone and $22 billion for the year, a pretty good return for the greatest rebounder since Dennis Rodman.

This farce is no longer funny any more. It’s no longer enough for Republicans to merely inveigh against mandates while asserting the shots don’t stop transmission. The shots and Paxlovid actually have negative efficacy and many known and unknown side effects. They need to be immediately pulled from the market, the entire approval process needs to be investigated and overhauled, and legislation needs to be established to prevent this from ever happening again, including provisions limiting liability protections and government endorsement and funding of such emergency products.

There’s been much acerbic debate surrounding the Atlantic article by Emily Oster calling for a “pandemic amnesty” for those who pushed these demonic policies on the public. The piece was rightfully maligned by the public because the perpetrators of COVID fascism never even admitted they were wrong. But it’s worse than that. They haven’t even stopped the implementation of this iteration of biomedical terrorism and are already working on the next steps. They are still pushing these same shots and other similar ones in production without any liability. They are still blocking research and treatment of COVID and vaccine injury. They are still engaging in gain-of-function research. And they still have not even signed on to legislation ending the president’s ability to indefinitely declare a public health emergency, regulate human bodily autonomy, and discriminate against people for personal health care choices.

Thus, it’s no longer even about the malfeasance of lockdowns and mandates, as horrific as they were. They are still promoting death shots and the proliferation of the technologies, surveillance, and biomedical security apparatus that allowed them to enter the bodies of the supermajority of adults in the world. Every single biomedical product pushed on the American people – from the shots and Paxlovid to remdesivir – were extremely dangerous and destructive. Republicans cannot simply walk away from this without legislation imposing basic liability exposure on the drug makers, investigating those behind the maleficent approval, and preventing this from happening in the future.

We thought the era of human experimentation was buried with the Nuremberg trials, but clearly there is a need to reaffirm the Nuremberg Code with Nuremberg 2.0 to ensure that the worst pharma actors are not the ones with the greatest exemptions from human rights violations.

CDC director tests positive for COVID-19 again



Centers for Disease Control and Prevention Director Dr. Rochelle Walensky, who tested positive for COVID-19 earlier in October, took a course of Paxlovid, tested negative, and then tested positive again, according to the CDC.

"CDC Director Dr. Rochelle P. Walensky experienced mild symptoms from her recent COVID-19 infection, completed a course of Paxlovid, and, after a period of isolation, tested negative for the virus. On Sunday, Dr. Walensky began to develop mild symptoms and has again tested positive. Consistent with CDC guidelines, she is isolating at home and will participate in her planned meetings virtually," the CDC noted on Monday.

Earlier in October, when Walensky first tested positive, the CDC noted that she was "up to date with her vaccines" and that she only had "mild symptoms."

Walensky received an updated COVID-19 vaccine shot in September.

"Today, I received my updated #COVID19 vaccine!" a tweet on the @CDCDirector Twitter account noted in September. "Laboratory data suggest these updated vaccines provide increased protection against currently circulating variants. If you received your last COVID-19 vaccine >2 mo. ago, I encourage you to join me & get your updated vaccine now."

Days after the announcement of Walensky's initial positive test, President Joe Biden received an updated COVID-19 vaccine jab, and urged others to follow suit. "Update ... your COVID vaccine. It's incredibly effective. But the truth is, not enough people are getting it," Biden said.

Biden tested positive for COVID-19 earlier this year after having already been fully vaccinated and boosted twice. Biden took Paxlovid, and physician to the president Dr. Kevin O'Connor noted that Biden tested negative before testing positive again. "This in fact represents 'rebound' positivity," O'Connor noted in a memo.

Similarly, National Institute of Allergy and Infectious Diseases Director Dr. Anthony Fauci tested positive earlier this year despite having been fully vaccinated and twice boosted. He too took Paxlovid, tested negative, and then tested positive again.

Foreign Policy Global Health Forum 2022 youtu.be

Some people who take Pfizer's Paxlovid experience a terrible taste in their mouth as a side effect



Some people who take Pfizer's Paxlovid endure the unpleasant experience of having a horrible taste in their mouth, according to the Wall Street Journal, which noted that the problem is informally termed "Paxlovid mouth."

The outlet reported that Jeanette Witten, 56, has described the foul flavor as being "like your mouth is just clenched around a grapefruit rind."

Lisa Crawford, 35, said, "It was like the smell that hot garbage has, but in your mouth." She said that eating pineapple helped her cope — she ate some each 10 to 15 minutes. "I probably have no tooth enamel left," she said, "but it was the only thing that saved my sanity."

Andrea Freire, 40, said that she drank four bottles of strawberry Pedialyte per day for three to four days in an attempt to cover up the taste. But the outlet reported that she considered it a no-brainer to take Paxlovid again when she had COVID-19 one month later. "I would take it again 100 times over," she said.

The side effect is known as dysgeusia, and the Wall Street Journal reported that a Pfizer spokesperson highlighted a study that indicates the issue appeared 5.6% of the time individuals took the medication. That Pfizer-funded study appeared in the New England Journal of Medicine, according to the outlet.

White House COVID-19 response coordinator Dr. Ashish Jha has said that COVID-19 deaths in the U.S. would drop to nearly zero if people would keep up-to-date on their COVID-19 vaccinations and take Paxlovid.

Paxlovid, which involves a course of nirmatrelvir tablets and ritonavir tablets, is used to treat people who have COVID-19.

Pfizer chairman and CEO Albert Bourla, who had received four vaccine shots, recently announced that he tested positive for COVID-19.

"I would like to inform the public that I have tested positive for COVID-19. I am grateful to have received four doses of the Pfizer-BioNTech vaccine and I am feeling well while experiencing very mild symptoms. I have started a course of PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets), I am isolating in place as well as following all public health precautions," Bourla said in a statement.

White House COVID-19 response coordinator claims that COVID deaths would nearly be eliminated if people would get their vaccinations and use Paxlovid



White House COVID-19 response coordinator Dr. Ashish Jha has claimed that coronavirus fatalities in the U.S. would drop to almost zero if everyone would stay up to date on their COVID-19 vaccinations and take Paxlovid.

"If everybody was up to date on their vaccines and people got treated with Paxlovid ... deaths would go to close to zero across America," he said.

Paxlovid can be used to treat people who have contracted COVID-19.

\u201cDr. Ashish Jha: "Right now we have 400 to 500 Americans still dying every day. If everybody was up to date on their vaccines and people got treated with Paxlovid as they're supposed to, deaths would go to close to zero across America."\u201d
— Scott Morefield (@Scott Morefield) 1660678503

Well-known public figures who have taken multiple vaccine shots have still tested positive for the illness.

Pfizer chairman and CEO Albert Bourla, who had received four vaccine shots, recently announced that he tested positive for COVID-19.

Dr. Anthony Fauci, who serves as chief medical advisor to President Biden and director of the National Institute of Allergy and Infectious Diseases, tested positive for the illness in June despite having already been fully vaccinated and twice boosted. Fauci later noted that after testing positive, he took a course of Paxlovid, and then tested negative for several days. He then tested positive again and proceeded to take another round of Paxlovid.

U.S. Defense Secretary Lloyd Austin tested positive on Monday after having previously tested positive earlier this year.

Despite the vaccine's clear failure to prevent people from contracting COVID-19, public health officials have continued to push for people to get jab after jab.

"Almost nothing in medicine cuts risk of death by 96%," Jha tweeted earlier this month. "Almost nothing Except the COVID vaccines," he added. "Double boosted folks had 96% lower risk of death compared to unvaccinated," he said. "If you're 50 or older and haven't gotten a vaccine in 2022," he wrote. "Please go get one now It may save your life."

"Being up to date on COVID-19 vaccination provides strong protection against severe disease, hospitalization, and death in all age groups. All eligible children, adolescents, and adults should remain up to date with recommended COVID-19 vaccinations," the Centers for Disease Control and Prevention website declares.

Chris Sweda/Chicago Tribune/Getty Images

If Paxlovid causes more COVID, why has the White House spent billions on it?

Is there some sort of unholy union between the FDA, Pfizer, and the Biden White House?

President Biden tests positive for COVID again in 'rebound' positivity case, will be under 'strict isolation procedures'



President Joe Biden has tested positive for COVID-19 again. The White House doctor claims that Biden, 79, is experiencing a "rebound" positivity case, and will be under "strict isolation procedures."

On Saturday afternoon, President Biden wrote on Twitter, "Folks, today I tested positive for COVID again. This happens with a small minority of folks. I’ve got no symptoms but I am going to isolate for the safety of everyone around me. I’m still at work, and will be back on the road soon."

White House physician Kevin O'Connor delivered an update on President Biden's health on Saturday.

"As described last week, acknowledging the potential for so-called 'rebound' COVID positivity observed in a small percentage of patients treated with PAXLOVID, the President increased his testing cadence, both to protect people around him and to assure early detection of any return of viral replication," O'Connor said.

"After testing negative on Tuesday evening, Wednesday morning, Thursday morning, and Friday morning, the President tested positive late Saturday morning, by antigen testing," he continued. "This in fact represents 'rebound' positivity."

"The President has experienced no reemergence of symptoms, and continues to feel quite well," O'Connor said. "This being the case, there is no reason to reinitiate treatment at this time, but we will obviously continue close observation."

O'Connor said President Biden would be under "strict isolation procedures."

\u201cAn update from Dr. Kevin O\u2019Connor, Physician to the President.\u201d
— The White House (@The White House) 1659205987

In June, Dr. Anthony Fauci also experienced a "Paxlovid rebound" after recovering from COVID and then getting reinfected days later.

Last month, the chief medical adviser to President Joe Biden said he experienced symptoms much worse in the second bout than the first.

“After I finished the five days of Paxlovid, I reverted to negative on an antigen test for three days in a row," Fauci said during Foreign Policy's Global Health Forum.

“And then on the fourth day, just to be absolutely certain, I tested myself again,” he said. “I reverted back to positive.”

"It was sort of what people are referring to as a Paxlovid rebound," Fauci added.

CNN reported, "Pfizer, the company that makes Paxlovid, says its studies show rebounds are rare and happen in people who take the drug as well as those who took a placebo pill. Because investigators noted the phenomenon in both groups, the company doesn't believe it is tied to the medication."

Fauci says he's back on Paxlovid after 'rebound' of COVID-19 symptoms



After testing positive for COVID-19 earlier this month, White House chief medical adviser Dr. Anthony Fauci revealed Wednesday he's experiencing a "rebound" of coronavirus symptoms after taking Pfizer's antiviral drug Paxlovid.

Fauci, 81, contracted COVID-19 about two weeks ago and initially experienced mild symptoms from the disease. He is fully vaccinated and has been boosted twice. But when his symptoms worsened because of his advanced age, doctors prescribed a five-day regimen of Paxlovid to treat him.

Paxlovid is a COVID-19 pill manufactured by Pfizer that has received emergency use authorization from the U.S. Food and Drug Administration to treat people at high risk of severe disease. The drug showed an 89% reduction in risk of hospitalization and death among COVID-19 patients in clinical trials and has been described as a "game changer" for the pandemic.

Following his Paxlovid treatment, Fauci reported that he felt "really quite well" and had tested negative for COVID, according to ABC News.

However, Fauci revealed Tuesday that he has tested positive for COVID again after testing negative for three consecutive days.

"It was sort of what people are referring to as a Paxlovid rebound," Fauci said while speaking via teleconference to the Foreign Policy Global Health Forum.

Fauci said he began to feel "really poorly" and "much worse than in the first go-around."

He has begun a second course of Paxlovid to treat his symptoms.

Several coronavirus patients have reported a similar "rebound" of symptoms after taking Paxlovid, which has prompted the U.S. Centers for Disease Control and Prevention to issue a health advisory on the matter.

"Paxlovid continues to be recommended for early-stage treatment of mild to moderate COVID-19 among persons at high risk for progression to severe disease," the CDC said on May 24.

"A brief return of symptoms may be part of the natural history of SARS-CoV-2 (the virus that causes COVID-19) infection in some persons, independent of treatment with Paxlovid and regardless of vaccination status," the agency advised.

The CDC said those reporting a "Paxlovid rebound" had mild symptoms and that there were no reports of severe disease after taking the drug.

"There is currently no evidence that additional treatment is needed with Paxlovid or other anti-SARS-CoV-2 therapies in cases where COVID-19 rebound is suspected," the CDC said.

Fauci, who has served as the director of the National Institute for Allergy and Infectious Diseases for more than three decades, is one of many people who have tested positive for COVID-19 despite being fully vaccinated.

Biden's FDA prioritizes race in administering life-saving COVID therapeutics; 'Latinx ethnicity' a higher priority in Utah than those with congestive heart failure



For Americans suffering from COVID-19 and seeking life-saving treatment, they may find themselves put on a waitlist depending on their skin color. The Food and Drug Administration, as well as multiple states, will prioritize race and ethnicity in determining who receives hard-to-get COVID-19 therapeutics. In some cases, even those with dangerous health conditions could be passed over for someone who is "non-white."

GlaxoSmithKline's sotrovimab is reportedly the only monoclonal antibody treatment that is effective against the Omicron variant — however, it is in very short supply.

The FDA's "fact sheet" for sotrovimab presents health care providers with a guidance on the emergency use authorization of the treatment. There is a "patient selection" section that outlines who should receive the sotrovimab treatment, especially since it is in limited availability at this time. The fact sheet lists "medical conditions or other factors may place adults and pediatric patients at higher risk for progression to severe COVID-19." Some of the conditions on the list include being aged 65 or older, obesity, chronic kidney disease, diabetes, and cardiovascular disease.

The guidance also adds a stipulation:

Other medical conditions or factors (for example, race or ethnicity) may also place individual patients at high risk for progression to severe COVID-19, and authorization of sotrovimab under the EUA is not limited to the medical conditions or factors listed above.

The Centers for Disease Control and Prevention states that high-risk individuals include people over age 65 and those with underlying medical conditions.

The CDC also proclaims:

Long-standing systemic health and social inequities have put various groups of people at increased risk of getting sick and dying from COVID-19, including many people from certain racial and ethnic minority groups and people with disabilities.

Studies have shown people from racial and ethnic minority groups are also dying from COVID-19 at younger ages. People in minority groups are often younger when they develop chronic medical conditions and may be more likely to have more than one condition.

Some states have adopted the guidances from the FDA and CDC that prioritizes race or ethnicity when determining who receives the therapeutic.

Last month, Minnesota released the state's "Ethical Framework for Allocation of Monoclonal Antibodies during the COVID-19 Pandemic" guidance.

The FDA has acknowledged that in addition to certain underlying health conditions, race and ethnicity "may also place individual patients at high risk for progression to severe COVID-19.' FDA’s acknowledgment means that race and ethnicity alone, apart from other underlying health conditions, may be considered in determining eligibility for mAbs. It is ethically appropriate to consider race and ethnicity in mAb eligibility decisions when data show elevated risk of poor COVID-19 outcomes for Black, Indigenous and other people of color (BIPOC populations), and that this risk cannot be adequately addressed by determining eligibility based on underlying health conditions (perhaps due to underdiagnosis of health conditions that elevate risk of poor COVID-19 outcomes in these populations).

The guidance adds, "At the present time, MDH has found that available data show this elevated risk."

In Utah, the state released its "Crisis Standards of Care Monoclonal Antibody Allocation Guidelines."

The guideline provides a risk score based on risk factors such as age and obesity and assigns a point value to each factor. Shockingly, being "Non-White race or Hispanic/Latinx ethnicity" holds a higher risk value than high-risk co-morbidities such as hypertension, coronary artery disease, cardiac arrhythmia, congestive heart failure, chronic kidney disease, chronic pulmonary disease, chronic liver disease, cerebrovascular disease, chronic neurologic disease, and those suffering from shortness of breath.

Utah Department of Health

Earlier this month, TheBlaze reported on the New York state government's decision to prioritize non-white people to receive COVID-19 treatments because of "longstanding systemic health and social inequities."

When it comes to the distribution of monoclonal antibodies as well as the new oral antiviral pills — Pfizer's Paxlovid and Merck's molnupiravir — New York's Department of Health declares, "Non-white race or Hispanic/Latino ethnicity should be considered a risk factor, as longstanding systemic health and social inequities have contributed to an increased risk of severe illness and death from COVID-19."

New York will prioritize non-white people when distributing lifesaving COVID treatments



As COVID-19 rips through New York, the state government has decided to prioritize non-white people to receive COVID-19 treatments because of "longstanding systemic health and social inequities."

Last week, New York’s Department of Health released a document titled: "Prioritization of Anti-SARS-CoV-2 Monoclonal Antibodies and Oral Antivirals for the Treatment of COVID-19 During Times of Resource Limitations Introduction." The memo provides a hierarchy of who should receive the limited supplies of monoclonal antibodies as well as the new oral antiviral pills — Pfizer's Paxlovid and Merck's molnupiravir — that were approved by the U.S. Food and Drug Administration last week under Emergency Use Authorization.

New York state offers a framework on which individuals should receive priority for COVID-19 treatments based on "risk factors," which include those who are immunocompromised, those who are aged 65 or older, and those who are overweight.

There is also a "note" that states that any COVID-infected people who are non-white should receive priority for treatment over white people because of "inequities."

"Non-white race or Hispanic/Latino ethnicity should be considered a risk factor, as longstanding systemic health and social inequities have contributed to an increased risk of severe illness and death from COVID-19," New York’s Department of Health states.

NY State Department of Health warns they don't have enough Paxlovid or Monoclonal Antibody Treatment and white people need not apply. http://www.mssnyenews.org/wp-content/uploads/2021/12/122821_Notification_107774.pdf\u00a0\u2026pic.twitter.com/MwBtjv2pDx
— Karol Markowicz (@Karol Markowicz) 1640916049

Erin Silk, a spokesperson for the New York Department of Health, told Fox News, "Systemic poverty, which has clearly proven to be a risk factor in populations in New York State and nationwide, is added to the algorithm of prioritization similar to all other risk factors. It is merely mentioned as a factor that increases risk."

The spokesperson noted that the state's "prioritization guidance comes directly from the CDC," adding "Race nor ethnicity would disqualify an individual from receiving treatment."

The Centers for Disease Control and Prevention states, "Race and ethnicity are risk markers for other underlying conditions that affect health, including socioeconomic status, access to health care, and exposure to the virus related to occupation, e.g., frontline, essential, and critical infrastructure workers."

The New York City Department of Health also recommends that race should be considered when prioritizing who receives monoclonal antibodies and oral antiviral pills for COVID-19.

"Consider race and ethnicity when assessing individual risk, as longstanding systemic health and social inequities may contribute to an increased risk of getting sick and dying from COVID-19," the memo to providers reads.

In May, Dr. Anthony Fauci claimed that the COVID-19 pandemic exposed "the undeniable effects of racism" in America.

"Now, very few of these comorbidities have racial determinants," said the chief medical adviser to President Joe Biden. "Almost all relate to the social determinants of health dating back to disadvantageous conditions that some people of color find themselves in from birth regarding the availability of an adequate diet, access to health care, and the undeniable effects of racism in our society."

FDA authorizes pills to treat COVID — but there's a catch



As concern over COVID -19 rises with the spread of the Omicron variant, a new form of treatment for the virus has arrived in the form of oral tablets, but there’s a catch: The medication must be taken quickly to be effective.

The FDA issued an emergency use authorization last week for oral pills made by Pfizer and Merck to treat the virus. Both Pfizer’s Paxlovid and Merck’s molnupiravir are designed to treat people with mild to moderate symptoms who are at risk of hospitalization or death, according to the FDA.

However, the FDA advises that the pills should be taken as soon as possible to be effective.

Both medications should be taken within a five-day window of the initial development of symptoms, according to a report from the Associated Press. Paxlovid comes in three-pill doses that must be taken twice a day for five days. Some pharmacies should be able to test a patient and prescribe the medication in the same visit, according to the AP. Patients hospitalized for COVID after being prescribed Paxlovid should complete the five-day treatment unless otherwise directed by their doctors, according to a fact sheet released by the FDA.

Pfizer's and Merck's treatments are both effective at reducing hospitalization or death as a result of a COVID infection, according to the FDA studies; however, Pfizer's treatment is considered to be far more effective. Pfizer's treatment has shown an 88% effectiveness rate at reducing hospitalization and death, according to the FDA studies. Molnupiravir has not been approved for individuals younger than 18. The FDA expressed concern that molnupiravir may affect bone and cartilage growth in patients under the age of 18. The FDA said that Paxlovid, on the other hand, may be taken by children as young as 12 or who weigh about 88 pounds, according to a statement released Wednesday. Paxlovid is not recommended for patients with kidney or liver problems.

“If you wait until you have started to get breathless, you have already to a large extent missed the window where these drugs will be helpful,” Duke University infectious disease specialist Dr. Cameron Wolfe told the AP, stressing the importance of taking the medication as soon as possible.

Some health professionals have expressed concern that the pills may have serious life-threatening side effects if taken by individuals who are currently taking many common medications, including but not limited to blood thinners; anti-seizure medications; drugs for irregular heart rhythms, high blood pressure, and high cholesterol; and antidepressants, according to NBC.

“Some of these potential interactions are not trivial, and some pairings have to be avoided altogether,” Peter Anderson, professor of pharmaceutical sciences at the University of Colorado Anschutz Medical Campus, told NBC on Sunday.

The Biden administration announced in November that it would purchase 10 million courses of Paxlovid to combat COVID-19. The plan will cost about $5 billion, according to the Washington Post.